Thyrocare Technologies Share Price Target 2026, 2027, 2030, 2040, 2050

Thyrocare Technologies is a well-known Indian diagnostic company and India’s first fully automated lab that offers affordable blood tests and health check-ups across the country. It uses modern machines to give fast and accurate test reports that doctors trust. The company provides more than 900 tests and health packages for thyroid, diabetes, cancer screening, and general health, for both hospitals and individuals. Since 2021, Thyrocare has been owned by API Holdings (PharmEasy Group) and focuses on giving good-quality medical tests at low prices across India.

What is Thyrocare Technologies Ltd NSE: THYROCARE?

Thyrocare Technologies was established in 1995, situated in Navi Mumbai, Maharashtra, and owned by API Holdings (PharmEasy Group). It is an Indian medical testing company that provides blood tests and health check-ups at affordable prices using modern machines for fast and accurate results. The company offers tests for thyroid, diabetes, heart health, and full body check-ups across many cities in India, and mainly focuses on preventive healthcare to help people detect health problems early.

Thyrocare Technologies Share Price Target

Thyrocare Technologies Share Price Target 2026

It is a well-established Indian company that offers medical testing services and comprehensive health check-ups. The company mainly works in laboratory testing, which helps people find health problems early and keep track of their health regularly. The company uses modern machines and technology for testing. Over the years, the company has gained the trust of doctors, hospitals, clinics, and patients across India. Its services are affordable, so people from different income groups can use them. Today, Thyrocare plays an important role in preventive healthcare in India. In 2026, its share price target would be ₹735, as per stock market analysts.

According to stock market analysts, its share price would be between ₹372 to ₹735 in 2026.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2026	372	735

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	388	540
February	372	578
March	380	590
April	390	611
May	445	632
June	480	645
July	500	659
August	521	671
September	532	688
October	554	698
November	600	712
December	615	735

Thyrocare Technologies Share Price Target 2027

It is known as India’s first fully automated diagnostic laboratory. Automation means that machines do most of the testing work instead of people. This helps reduce mistakes and improve the accuracy of test results. Automation also helps in giving the same quality results every time. Because of this system, Thyrocare can test a large number of samples every day without losing quality. Reports are delivered faster compared to many old-style laboratories. In 2027, its share price target would be ₹1086, as per stock market analysts.

According to stock market analysts, its share price would be between ₹690 to ₹1086 in 2027.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2027	690	1086

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	690	811
February	700	832
March	721	850
April	737	878
May	750	890
June	774	930
July	790	955
August	832	984
September	855	1021
October	890	1042
November	935	1060
December	956	1086

Share Price Target 2028

It mainly focuses on preventive healthcare, not just treating diseases after they happen. Preventive healthcare means finding health problems early before they become serious. The company encourages people to go for regular health checkups to check sugar, cholesterol, thyroid, vitamins, hormones, and other important health factors. It offers different health packages for people of different ages and lifestyles. These packages help people understand their health better and take action at the right time. Preventive testing also helps reduce future medical costs and supports a healthier life. In 2028, its share price target would be ₹1451, as per stock market analysts.

According to stock market analysts, its share price would be between ₹1050 to ₹1451 in 2028.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2028	1050	1451

Share Price Target 2029

It offers many types of medical tests related to different health problems. These include tests for thyroid issues, diabetes, heart health, liver and kidney health, hormones, vitamin levels, infections, and cancer signs. The company also provides full body checkup packages that include many tests in one plan. This helps patients get a complete health report in one visit. By offering many tests under one brand, it becomes a single place for diagnostic needs. This saves time and effort for both patients and doctors. In 2029, its share price target would be ₹1838, as per stock market analysts.

According to stock market analysts, its share price would be between ₹1400 to ₹1838 in 2029.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2029	1400	1838

Thyrocare Technologies share price Target 2030

The company uses modern testing machines that follow international quality standards. These machines can find even very small health changes, which helps in early disease detection. Digital systems are used to track samples, process results, and send reports correctly. Technology also helps in faster testing, so patients get their reports quickly. It keeps upgrading its machines to match new medical developments. This strong use of technology helps provide accurate and reliable test results. In 2030, its share price target would be ₹2250, as per stock market analysts.

According to stock market analysts, its share price would be between ₹1790 to ₹2250 in 2030.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2030	1790	2250

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	1790	1907
February	1811	1925
March	1832	1941
April	1857	1968
May	1867	1988
June	1887	2024
July	1912	2054
August	1952	2074
September	1974	2125
October	2025	2158
November	2078	2190
December	2120	2250

Share Price Target 2040

It has a large network across India and works in thousands of cities and towns. Its many sample collection centres make it easy for people to get tests done near their homes. Even people in small towns can use advanced testing because their samples are sent safely to central laboratories. This wide network helps reduce the gap between city and rural healthcare services. The company’s ability to serve so many people shows its strong planning and smooth working system. Easy access is one main reason for its growing popularity. In 2040, its share price target would be ₹4140, as per stock market analysts.

According to stock market analysts, its share price would be between ₹3650 to ₹4140 in 2040.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2040	3650	4140

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	3650	3774
February	3678	3790
March	3690	3821
April	3711	3845
May	3742	3874
June	3765	3900
July	3820	3932
August	3841	3958
September	3868	3987
October	3890	4051
November	3921	4088
December	3980	4140

Share Price Target 2050

The company employs skilled technicians, scientists, and support staff who handle complex medical tests. Employees are trained to follow strict quality rules. The laboratories work day and night, which helps in quick sample testing and fast report delivery. Efficient working systems allow the company to handle large numbers of tests without delays. This smooth and reliable system is very important in the healthcare diagnostics industry. In 2050, its share price target would be ₹6307, as per stock market analysts.

According to stock market analysts, its share price would be between ₹5816 to ₹6307 in 2050.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2050	5816	6307

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	5816	5930
February	5850	5957
March	5867	5982
April	5884	6021
May	5921	6057
June	5950	6078
July	5974	6090
August	5990	6125
September	6012	6157
October	6055	6221
November	6145	6278
December	6200	6307

Should I buy Thyrocare Technologies stock?

Year	Minimum Price (Rs)	Maximum Price (Rs)
2026	372	735
2027	690	1086
2028	1050	1451
2029	1400	1838
2030	1790	2250
2040	3650	4140
2050	5816	6307

It is a famous Indian company that provides medical tests and health checkups to help people stay healthy. It is trusted for giving accurate results, using modern machines, and offering many types of tests for people in cities and small towns. The company has grown steadily, making good profits, with low debt and strong cash, which shows it is financially safe. It could be a good choice for long-term investors.

Thyrocare Technologies earnings results

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales +	434	495	589	527	572	687	763
Expenses +	261	323	353	403	432	498	535
Operating Profit	174	171	236	123	140	190	228
OPM %	40%	35%	40%	23%	24%	28%	30%
Other Income +	1	12	29	9	9	15	17
Interest	2	1	3	5	6	4	3
Depreciation	32	30	34	39	47	55	54
Profit before tax	140	152	228	89	96	145	188
Tax %	37%	26%	23%	27%	28%	38%
Net Profit +	88	113	176	64	69	91	127
EPS in Rs	5.58	7.13	11.10	4.06	4.45	5.76	8.03
Dividend Payout %	30%	117%	45%	148%	135%	122%

Key Metrics

TTM PE Ratio	PB Ratio	Dividend Yield	Sector PE	Sector PB	Sector Div Yld
55.54	12.97	1.57%	36.45	5.78	0.60%

Peers & Comparison

Stock	PE Ratio	PB Ratio	Dividend Yield
Thyrocare Technologies Ltd	77.52	12.97	1.57%
Max Healthcare Institute Ltd	94.49	10.84	0.14%
Apollo Hospitals Enterprise Ltd	70.03	9.12	0.18%
Fortis Healthcare Ltd	86.20	7.28	0.11%

Is Thyrocare Technologies stock good to buy? (bull case & bear case)

Bull Case:

• The company’s net profit for FY 2025 was ₹128 crore, higher than ₹110 crore in FY 2024.
• In the last 12 months, the company earned ₹7.63 billion in revenue and ₹1.28 billion in net profit, showing strong performance.
• Sales and profit have generally increased over the years, showing steady business growth.
• In FY 2025, it earned ₹763 crore in total revenue, up from ₹635 crore in FY 2024, showing steady sales growth.
• It has very low debt and is almost debt-free, making it financially safer.
• Stock is trading at 13.5 times its book value.
• The company has been maintaining a healthy dividend payout of 135%, giving good returns to shareholders.
• The company’s working capital requirements have reduced from 17.1 days to 12.8 days, showing better efficiency.

Bear Case:

• The stock price is high compared to its book value, which may limit further gains.
• Promoter holding has decreased by -10.1% over the last quarter, which can worry investors.
• Promoters have pledged or encumbered 100% of their holding, which is a potential risk.
• The company has delivered a poor sales growth of 9.62% over the past five years.
• The company has a low return on equity of 13.9% over the last 3 years.

Conclusion

It is a well-known Indian company that provides medical tests and health check-ups. It is the first fully automated lab in India and gives fast and accurate results using modern machines. The company helps people stay healthy by finding problems early. It is owned by API Holdings and is financially strong with low debt and regular dividend payments. Even though there are some risks from competition and promoter shares, it is trusted and can be a good choice for people who want to invest for a long time in healthcare.

FAQs